TMEM70: A Potential Drug Target for ALS and Other Neurodegenerative Disorders

Target Name: TMEM70

NCBI ID: G54968

TMEM70

TMEM70: A Potential Drug Target for ALS and Other Neurodegenerative Disorders

TMEM70 (Tissue Membrane Extender 70) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a member of the superfamily of transmembrane protein (TM) transporters, which are a group of proteins that are involved in the transport of various molecules across the membrane of the cell.

TMEM70 is one of the proteins that is known to be involved in the transport of a substance called Sphingomyelin (SM), which is a type of lipid molecule that is involved in the formation of the cell membrane and the delivery of various molecules to the cell surface. Sphingomyelin is also known as a biomarker for various diseases, including ALS (Amyotrophic Lateral Sclerosis), a progressive neurodegenerative disorder that affects muscle strength and function.

Research has shown that TMEM70 is involved in the regulation of the levels of Sphingomyelin in various tissues, including the brain. Studies have shown that TMEM70 is expressed in the brain and that it is involved in the transport of Sphingomyelin to the brain surface. This suggests that TMEM70 may be a drug target (or biomarker) for the treatment of ALS and other neurodegenerative disorders.

In addition to its involvement in the transport of Sphingomyelin, TMEM70 is also known to be involved in the regulation of various cellular processes that are important for the function of the cell. For example, studies have shown that TMEM70 is involved in the regulation of the levels of neurotransmitters, such as dopamine and GABA, in the brain. This suggests that TMEM70 may be involved in the treatment of disorders that are characterized by the overuse or deficiency of these neurotransmitters, such as Parkinson's disease and schizophrenia.

Another potential role for TMEM70 is its involvement in the regulation of the structure and function of the cell membrane. Studies have shown that TMEM70 is involved in the formation of the transmembrane structure of the Sphingomyelin channel, which is responsible for the transport of Sphingomyelin to the cell surface. This suggests that TMEM70 may be involved in the treatment of disorders that are characterized by the disruption of the cell membrane structure, such as those caused by bacterial or viral infections.

In conclusion, TMEM70 is a protein that is involved in the transport of Sphingomyelin to various tissues throughout the body, including the brain. Its involvement in the regulation of cellular processes that are important for the function of the cell and the maintenance of the cell membrane structure suggests that TMEM70 may be a drug target (or biomarker) for the treatment of various neurodegenerative disorders, including ALS. Further research is needed to fully understand the role of TMEM70 in these disorders and to develop effective treatments.

Protein Name: Transmembrane Protein 70

Functions: Scaffold protein that participates in the c-ring assembly of mitochondrial ATP synthase (F(1)F(0) ATP synthase or complex V) by facilitating the membrane insertion and oligomer formation of the subunit c/ATP5MC1 through its interaction (PubMed:31652072, PubMed:33753518, PubMed:33359711, PubMed:32275929). Therefore, participates in the early stage of mitochondrial ATP synthase biogenesis and also protects subunit c/ATP5MC1 against intramitochondrial proteolysis (PubMed:33359711, PubMed:18953340, PubMed:20937241, PubMed:31652072). In addition, binds the mitochondrial proton-transporting ATP synthase complexes I and may play a role in the stability of its membrane-bound subassemblies (PubMed:32275929)

The "TMEM70 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM70 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets